US-based Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of Quintis Ltd. of Perth, Australia (ASX:QIN). Santalis was formed to develop a range of OTC and prescription products based on the botanical drug substance produced by Quintis' Santalum album trees. Santalis has the world-wide exclusive rights to Quintis' Sandalwood Album Oil (SAO) for healthcare uses. Quintis is the world's largest producer of this essential oil and is the only supplier of pharmaceutical grade SAO from sustainably-grown trees. Santalis is developing SAO under the FDA's botanical drug development guidelines, with a current focus on dermatology. Indications of particular interest include acne, rosacea, atopic dermatitis/eczema, psoriasis and viral skin diseases such as Molluscum contagiosum and warts caused by human papilloma virus (HPV).

Santalis Pharmaceuticals

Org chart

Teams

Offices